secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001628280-25-058594
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen's PALISADE-3 Phase 3 study of fasedienol fails primary endpoint in social anxiety disorder
--------------------------------------------------------------------------------

- LS mean change from baseline on SUDS score: fasedienol 13.6 (SE 1.54) vs placebo 14.0 (SE 1.51); no statistical significance.
- Secondary endpoints also showed no treatment difference between fasedienol and placebo.
- Favorable safety data consistent with prior trials; no new safety signals.
- Phase 3 failure likely halts development path for intranasal fasedienol in acute social anxiety.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828025058594/0001628280-25-058594-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828025058594/vtgn-20251217.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-058594

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer